Conference Coverage: ASCO GU 2023 Highlights
Expert perspectives and strategic insights on the latest therapeutic developments in GU cancer treatment from the 2023 ASCO GU Cancers Symposium, and implications on individualized clinical decision-making.
FACULTY CHAIR
Daniel Petrylak, MD
Yale Cancer Center, New Haven, CT, USA
Faculty Members
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA
Karim Fizazi, MD, PhD
Gustave Roussy, Villejuif, France
Leonard Gomella, MD
Sidney Kimmel Cancer Center, Philadelphia, PA, USA
Thomas Powles, MD, MBBS, MRCP
Barts Cancer Centre, London, United Kingdom
Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
A report will be produced that is based on the meeting, and will discuss the following topics
- Prostate Cancer Part 1 – Hormonal Therapies and Chemotherapies
- Prostate Cancer Part 2 – Targeted Therapies
- Bladder Cancer Part 1 – ADCs
- Bladder Cancer Part 2 – PARP Inhibitors and Immunotherapies
- Renal Cell Carcinoma
